Outlook Therapeutics, Inc. (Nasdaq: OTLK) announced that the U.S. Food and Drug Administration has approved LYTENAVA (bevacizumab-vikg) for the treatment ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA